Form 8-K SUTRO BIOPHARMA, INC. For: Mar 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Sutro Biopharma (STRO) PT Lowered to $11 at Piper Sandler
April 3, 2024 6:48 AM EDTPiper Sandler analyst Edward Tenthoff lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $11.00 (from $12.00) while maintaining a Overweight rating.
The analyst comments "Sutro partnered preclinical ROR1 ADC STRO-003 with Ipsen for $50 million upfront, $25 million equity investment, >$800 million in milestones plus low-double... More
Sutro Biopharma (STRO) PT Lowered to $18 at Truist Securities
April 2, 2024 4:12 PM EDTTruist Securities analyst Asthika Goonewardene lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $18.00 (from $25.00) while maintaining a Buy rating.
The analyst comments "In the next 12 months, we see 3 potential events that could be an inflection point to shares and/or... More
